福提斯

最新新闻

• 公司公告
  FTS Hengli Bond Fund(LOF)-A: Announcement regarding the addition of Jiaan Wealth (Peking) Fund Sales Co. Ltd. as a sales agency for some funds under Guohai Franklin Fund Management Co. Ltd. and the opening of conversion business, regular investment business, and related fee discount activities.
  SZSI · 2024/8/7
• 评级变动
  Barclays Maintains Fortis(FTS.US) With Buy Rating, Maintains Target Price $61
  \u5e02\u573a\u8d44\u8baf · 2026/7/1
• 评级变动
  Jefferies Maintains Fortis(FTS.US) With Hold Rating, Raises Target Price to $59.58
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• 公司公告
  ASKA Pharmaceutical Holdings: Collaboration with MedChoice Pharma, Inc. through the acquisition of shares of FTS Ambrose Holdings, Inc. (making it an affiliate applying the equity method)
  JPX · 2025/3/3
• J.P. Morgan Keeps Their Sell Rating on Fortis (FTS)
  TipRanks · 2026/9/2
• 评级变动
  J.P. Morgan Maintains Fortis(FTS.US) With Sell Rating, Raises Target Price to $56.33
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Jefferies Maintains Fortis(FTS.US) With Hold Rating, Raises Target Price to $57.87
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  Scotiabank Maintains Fortis(FTS.US) With Hold Rating, Cuts Target Price to $57.67
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• TD Cowen Maintains Fortis(FTS.US) With Buy Rating, Raises Target Price to $61.82
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• Barclays Maintains Fortis(FTS.US) With Buy Rating, Cuts Target Price to $56
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Wolfe Research Maintains Fortis(FTS.US) With Sell Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Barclays Maintains Fortis(FTS.US) With Buy Rating, Cuts Target Price to $58.39
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  RBC Capital Maintains Fortis(FTS.US) With Hold Rating, Raises Target Price to $63.43
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  RBC Capital Initiates Fortis(FTS.US) With Hold Rating, Announces Target Price $63.43
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• 评级变动
  BMO Capital Maintains Fortis(FTS.US) With Hold Rating, Raises Target Price to $59.1
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 公司公告
  ASKA Pharmaceutical Holdings: ASKA Pharmaceutical Holdings to Collaborate with MedChoice Pharma Inc through Share Acquisition of FTS Ambrose Holdings Inc.
  JPX · 2025/3/3
• 评级变动
  Desjardins Maintains Fortis(FTS.US) With Buy Rating, Raises Target Price to $60.39
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 公司公告
  ASKA Pharmaceutical Holdings: ASKA Executes Capital Increase to FTS AMBROSE HOLDINGS, INC.
  JPX · 2026/4/20
• CIBC Maintains Fortis(FTS.US) With Hold Rating, Cuts Target Price to $55.42
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 公司公告
  ASKA Pharmaceutical Holdings: Notice Regarding Additional Investment in FTS AMBROSE HOLDINGS, INC.
  JPX · 2026/4/20

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。